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INTRODUCTION1 
 The concept of drug delivery has been revolutionized. The 
strides have been made to lend patient derive maximum benefits of 
a drug. The drug should be delivered to a specific target sites at a 
rate and concentration that permit optimal therapeutic efficacy 
while reducing side effects to minimum. Another aspect to be 
considered in drug delivery is patient compliance during the drug 
therapy. 
 The concept of the advanced drug delivery systems especially 
those offering a sustained and controlled action of drug to desired 
area of effect, attained great appeal for nearly half a century. 
However, prior to the advent of improved alternative methods, drug 
delivery systems were considered only as a means of getting the 
drug into patient’s body. Actual practice of controlled release began 
with advent of timed release coating to the pills or solid drug 
particles in order to mask their unacceptable taste or make them 
palatable. 
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 Oral controlled release products are formulated to release 
active ingredient gradually and predictably over a 12 to 24hour 
period. These formulations potentially provide for greater 
effectiveness in the treatment of chronic conditions through more 
consistent delivery of the medication; reduced side effects; greater 
convenience; and higher levels of patient compliance due to a 
simplified dosage schedule, compared with those of immediate-
release drugs. 
DEFINITION2 
  Controlled drug delivery system is defined as the release of a 
drug or other active ingredient in a predesigned/ predetermined 
manner. The rationale for controlled delivery of drugs is to promote 
therapeutic benefits while at the same time minimizing toxic 
effects. Normal drug dosing follow a “saw tooth” kinetic profile, in 
which the dose first greatly exceeds the desired therapeutic level, 
then falls to subclinical level, and on subsequent dosing rises to 
dangerously high values, falling again to ineffective concentrations, 
in cycles of excessive- ineffective levels. Controlled, sustained drug 
delivery can reduce the undesirable fluctuation of drug levels, 
enhancing therapeutic action and eliminating dangerous side 
effects. 
Fig. No.1: Undesirable sawtooth kinetic profile under 
conditions of normal dosing and optimum therapeutic profile  
obtainable with controlled release 
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ADVANTAGES2 
¾ More effective therapies. 
¾ Elimination of the potential for both under and over 
 dosing. 
¾ Maintenance of drug levels within a desired range. 
¾ The need for fewer administrations. 
¾ Optimal use of drug in question. 
¾ Increased patient compliance. 
DISADVANTAGES2  
¾ The possible toxicity or non biocompatibility of the 
 materials used for the controlled release systems. 
¾ Undesirable by-products of degradation. 
¾ Any surgery required to implant or remove the system 
¾ The chance of patient discomfort from the delivery 
 device. 
¾ The higher cost of controlled release systems compared 
 with traditional pharmaceutical formulations. 
IDEAL PROPERTIES2 
 Based on the mentioned advantages and disadvantages of 
controlled release, one might formulate requirements for the “ideal” 
drug delivery system as follows. Such systems should be 
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 Inert 
 Biocompatible 
 Mechanically strong 
 Comfortable for the patient 
 Capable of achieving high drug loading 
 Safe from accidental drug release 
 Simple to administer and remove 
 Easy to fabricate and sterilize 
 If one were to imagine the ideal drug delivery system, two 
prerequisites would be required. First, it would be a single dose for 
duration of treatment, whether it is for days or week, as in 
infections, or for lifetime of the patient, as in hypertension or 
diabetes. Second, it should deliver the active entity (drug) directly 
to the site of action, thereby minimizing or eliminating side effects. 
This may necessitate delivery to specific receptors or to localization 
to cells or to specific areas of the body3. 
 The goal of many of the original sustained controlled release 
systems was to achieve a delivery profile that would yield a high 
blood level of the drug over a long period of time. The key point 
with traditional drug administration is that the blood level of the 
agent should remain between a maximum value which may 
represent a toxic level, and a minimum value below which the drug 
is no longer effective. In controlled drug delivery systems designed 
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for long term administration and sustained drug release, the drug 
level in the blood remains relatively constant, between a desired 
maximum and minimum, for an extended period of time. 
   It is obvious that this imaginary delivery system will have 
changing requirements for different disease states and different 
drugs. Thus, we wish to deliver the therapeutic agent to a specific 
site and for a specific time. In other words, the objective is to 
achieve both spatial and temporal placement of drug. Currently, it 
is possible to achieve both of these goals, with most drug delivery 
systems. The given pictorial representation in Fig No: 2 gives an 
idea about the sustained drug delivery system4. 
Fig.No. 2: plasma concentration Vs time profile 
 
FACTORS GOVERNING THE DESIGN OF SRDDS1 
 There are number of factors which may influence the design 
of any dosage form. Similarly design of sustained release dosage 
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form is governed by the factors listed below in table No: 1 
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Table.No.1: Factors governing the design of SRDDS 
Drug related 
Physicochemical 
properties of drug 
Aqueous solubility 
Partition coefficient 
Protein binding 
Molecular weight 
Drug stability 
Pharmacokinetic 
Absorption rate 
Elimination half life 
Rate of metabolism 
Dosage form index(DI) 
First pass metabolism 
Pharmacodynamic 
Therapeutic range 
Therapeutic index(TI) 
Plasma-concentration responses 
Route of administration 
Dose size 
Absorption efficiency 
Duration of action 
Pharmacological 
Changes in drug effect upon multiple 
dosing 
Sensitizing 
Tolerance 
Physiological 
Prolonged drug absorption 
Variability in GI emptying and motility 
GI blood flow 
 
CRITERIA OF DRUG SELECTION FOR SRDDS5,6 
 Characteristics of Drugs Unsuitable for oral SRDDS 
¾ Not effectively absorbed in the lower intestine   
 (eg:  Riboflavin, Ferrous salts, etc) 
¾  Absorbed and excreted rapidly; short biologic half-lives 
 (< 1hr) (eg: Penicillin G, furosemide, etc ) 
Chapter 7  Results  & 
Discussion 
 20 
¾  Long biologic half-lives (>12 hr) (eg:Diazepam, phenytoin, 
 etc) 
¾  Large doses required (>1g) ( eg: Sulfonamides) 
¾  Cumulative action and undesirable side effects; drugs with 
 low therapeutic indices (eg: Phenobarbital, digitoxin, etc)  
¾ Precise dosage titrated to individual is required   
 (eg:  Anticoagulants, cardiac glycosides, etc) 
¾ No clear advantage for sustained release formulation 
 (eg: Griseofulvin) 
 The following are the criteria to be met by drug proposed to 
be formulated in sustained release dosage forms.  
a) Desirable half-life 
 The half life of a drug is an index of its residence time in the 
body. If the drug has a short half life (less than 2 hours), the 
dosage form may contain a prohibitively large quantity of the drug. 
On the other hand, drug with elimination half life of eight hours or 
more are sufficiently sustained in the body, when administered in 
conventional dosage from, and controlled release drug delivery 
system is generally not necessary in such cases. Ideally, the drug 
should have half-life of three to four hours. 
b)  High Therapeutic Index 
 Drugs with low therapeutic index (eg: digitoxin) are 
unsuitable for incorporation in controlled release formulations. If 
the system fails in the body, dose dumping may occur, leading to 
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fatalities (eg. Digitoxin). 
c)  Small dose 
 If the dose of a drug in the conventional dosage form is 
high(>1g), its suitability as a candidate for controlled release is 
seriously undetermined (eg: antibiotics). This is chiefly because the 
size of a unit dose of new delivery system would become too big, to 
administer with difficulty. 
d)  Desirable absorption and solubility characteristics 
 Absorption of poorly water soluble drug is often dissolution 
rate limited. Incorporating such compounds into controlled release 
formulations is therefore unrealistic and may reduce overall 
absorption efficiency. 
e)  First pass clearance 
 Delivery of the drug to the body in desired 
concentrations is seriously hampered in case of drugs 
undergoing extensive hepatic first pass metabolism, when 
administered in controlled release forms. 
MICROSPHERES/ MICROCAPSULES1 
 The term microcapsule is defined as a spherical particle with 
size varying from 50nm to 2mm containing a core substance. 
Microspheres are in strict sense, spherical empty particles. 
However the term microcapsules and microspheres are often used 
synonymously. The microspheres are characteristically free flowing 
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powders consisting of proteins or synthetic polymers, which are 
biodegradable in nature, and ideally having a particle size less than 
200nm. Solid biodegradable microspheres incorporating a drug 
dispersed or dissolved throughout particle matrix have the 
potential for the controlled release of drug.  
DEVELOPMENT OF A MICROENCAPSULATION PROCEDURE7 
 The microspheres can be prepared by using any of several 
techniques discussed in the following sections but the choice of the 
technique mainly depends on the nature of the polymer used the 
drug, the intended use and the duration of therapy. Moreover, the 
method of preparation and its choice are equivocally determined by 
some formulation and technology related factors as mentioned 
below: 
 The particle size the final product required. 
 The drug or the protein should not be adversely affected 
 by the process. 
 Reproducibility of the release profile and the method. 
 No stability problem. 
 There should be no toxic product associated with the  final 
 product. 
 Different types of methods are employed for the preparation 
of the microspheres. These include single emulsion technique, 
double emulsion technique, in-situ polymerization, solvent 
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evaporation, coacervation phase separation, spray drying, spray 
congealing etc. 
SINGLE EMULSION TECHNIQUE1 
 The microparticulate carriers of natural polymers, i.e. those 
of proteins and carbohydrates are prepared by single emulsion 
technique. The natural polymers are dissolved or dispersed in 
aqueous medium followed by dispersion in the non-aqueous 
medium. In the second step of preparation, cross linking of the 
dispersed globule is carried out. The cross linking can be achieved 
either by means of heat or by using chemical cross linkers like 
glutaraldehyde, formaldehyde, diacid chloride etc. cross-linking by 
host is affected by adding the dispersion to previously heated oil. 
Heat denaturation is however, not suitable for the thermolabile 
drugs while the chemical cross-linking suffers disadvantage of 
excessive exposure of active ingredient to chemicals if added at the 
time of preparation. 
DOUBLE EMULSION TECHNIQUE1 
 Double emulsion method of microspheres preparation 
involves the formation of multiple emulsions or the double 
emulsion of the type w/o/w and is best suited to water soluble 
drugs, peptides, proteins and the vaccines. This method can be 
used with both the natural as well as synthetic polymers. The 
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aqueous protein solution is dispersed in a lipophilic organic 
continuous phase. This protein solution may contain the active 
constituents. The continuous phase is generally consisted of the 
polymer solution that eventually encapsulates of the protein 
contained in dispersed aqueous phase. The primary emulsion is 
then subjected to homogenization or sonication before addition to 
the aqueous solution of poly vinyl alcohol. This results in the 
formation of a double emulsion and the resultant is then subjected 
to solvent removal either by solvent evaporation or solvent 
extraction. 
POLYMERIZATION TECHNIQUES1 
 The polymerization techniques conventionally used for the 
preparation of the microspheres are mainly classified as: 
• Normal polymerization 
 Normal polymerization proceeds and carried out using 
different techniques as bulk, suspension, emulsion and miceller 
polymerization processes. 
• Interfacial polymerization 
 Interfacial polymerization essentially proceeds involving 
reaction of various monomers at the interface between the two 
immiscible liquid phases to form a film of polymer that essentially 
envelops the dispersed phase. 
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• Phase separation coacervation technique 
 The process is based on the principle of decreasing the 
solubility of the polymer in the organic phase to affect the 
formation of the polymer rich phase called coacervates. The 
coacervation can be brought about by addition of the third 
component to the system which results in the formation of the two 
phases, one rich in the polymer, while the other one, i.e. 
supernatant, deplete of the polymer. There are various means and 
methods, which are effectively employed for coacervate phase 
separation like salt addition, non-solvent addition, addition of 
incompatible polymer, change in pH etc. The method choice is 
largely dependent upon the polymer and set of conditions.  
• Spray drying and spray congealing 
 Spray drying and spray congealing methods are based on the 
drying of the mist of the polymer and drug in the air. Depending on 
the removal of the solvent or the cooling of the solution, the two 
processes are named spray drying and spray congealing 
respectively. 
• Solvent evaporation technique7 
 The oil-in-water (o/w) solvent evaporation method, also 
known as “in-water drying”, originally developed for the 
encapsulation of water insoluble drugs. The method involves the 
preparation of a solution of a wall forming polymer in a water- 
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immiscible organic solvent into which the drug is dissolved directly 
or with the aid of a cosolvent or dispersed in a fine state. This is 
then added in a controlled fashion into an aqueous solution of an 
emulsifying agent under intense agitation. It is generally not 
applicable to the encapsulation of highly water soluble peptides 
within hydrophobic polymers because upon emulsification of the 
dispersion of the drug-organic polymer solution/dispersion into the 
external aqueous phase, most of the peptides partitions out into 
the external phase resulting into negligible entrapment in the 
microspheres. 
 In 1970 a multiple emulsion solvent evaporation 
microencapsulation procedure was patented by Vrancken and 
Claeys and further by DeJaeger and Tavernier in 1971. In brief, an 
aqueous solution of the drug substance was emulsified under high-
speed homogenization or sonication into a solution of polymer in 
an organic solvent. This emulsion, known as the primary emulsion, 
was then poured under constant stirring into an external aqueous 
praise containing a suitable emulsifier.  
 For successful development of a microencapsulation 
procedure it is essential to have an excellent understanding and 
control on the polymer and its chemistry. 
POLYMERS7 
 One of the preliminary requirements in the successful 
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development of a microencapsulation procedure and in achieving a 
product of reproducible quality in terms of microencapsulation 
efficiency, yield, scale-up performance, and finally, drug release 
characteristics is the selection of a suitable polymer as the coating 
material and the complete characterization of the polymer. 
 
 The requirements for biodegradable polymer for drug delivery 
include controlled biodegradation rate, production of nontoxic 
degradation products and metabolites, reproducible and 
economically viable manufacturing process for large scale 
manufacture, absence of impurities such as residual solvents, 
catalysts, monomers, stabilizers etc and ease of processing 
PREREQUISITES FOR IDEAL MICROPARTICULATE CARRIERS1 
  The material utilized for the preparation of microparticulates 
should ideally fulfill the following prerequisites. 
¾ Longer duration of action   ¾ Control of content release 
¾ Protection of drug ¾ Reduction of toxicity 
¾ Biocompatibility ¾ Sterilizability 
¾ Relative stability ¾ Bioresorbability  
¾ Targetability ¾Tensile strength 
¾ Poly valent ¾  Transition temperature 
¾ Increase of therapeutic efficiency 
¾ Water solubility or dispersability 
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CLASSIFICATION OF POLYMERS 
The polymers are the important component as it decides the 
release of drug from sustained release dosage forms. The polymers 
are basically classified as  
1.  Biodegradable 
2.  Non biodegradable 
Table No.2: Classification of polymers 
Biodegradable polymers Non biodegradable polymers 
Poly esters eg: poly(glycolic 
acid), poly(lactic acid), 
poly(caprolactone), etc 
Poly ethylene vinyl acetate (EVA) 
Natural polymers eg: collagen, 
gelatin, albumin, starch, 
chitosan ,etc 
Poly ether urethane (PEU) 
Synthetic eg: poly amino acids, 
poly alkyl cyano acrylate, poly 
amides etc 
Poly vinyl chloride (PVC) 
Biodegradable polymers for microparticles 
 The biodegradable polymers comprised of monomers linked 
to one another through functional groups and have unstable 
linkages in the backbone. They are biologically degraded or eroded 
by enzymes or generated by surrounding living cells. 
 Biodegradable microparticles allow the drug release to be 
accurately tuned for the treatment of the Specific disease through 
the appropriate choice and formulation of specific drugs and 
polymers. Based on various microencapsulation techniques, 
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microparticles can be designed for optimum delivery of a selected 
bioactive agent. The resulting microparticles may offer the ability to 
improve the stability of therapeutic agents against hydrolytic or 
enzymatic degradation, to augment the therapeutic effect by 
releasing the drug into the specific site, and to sustain the 
therapeutic effect in the target site. Many synthetic and natural 
biodegradable polymers present exciting opportunities in tailor-
making the microparticle formulations for long-term drug release 
with specific release rates. 
THE ORGANIC SOLVENT7 
 In addition to the choice of the proper polymer for 
microencapsulation it is also essential to determine the appropriate 
solvent for the preparation. The selection of the solvent and the 
external continuous phase determine microsphere formation and 
entrapment efficiencies. A good solvent for microencapsulation 
should have the following properties: 
1) Good solvency of the polymer 
2) Poor solvency of the drug 
3) Low boiling point 
4) Should not cause the degradation of the drug substance 
5) Should be acceptable for human use 
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THE EXTERNAL PHASE7 
 The external phase in a solvent evaporation encapsulation 
method should be inexpensive, high boiling, non toxic and 
immiscible with organic solvent. The external phase should also 
contain an emulsifier. As the solvent evaporation proceeds to a 
completion the droplets generated initially shrink in size as the 
organic solvent evaporates. During this early evaporation stage the 
droplets tend to coalesce and form agglomerates. A good emulsifier 
is required for the stabilization of the droplets to prevent 
coalescence by the formation of a thin film. As the evaporation 
proceeds, the emulsifier film helps to maintain the spherical shape 
of the droplets till such time as the droplets are hardened enough 
to be harvested. 
DRUG RELEASE KINETICS1 
 Release of the active constituent is an important 
consideration in case of microspheres. Many theoretically possible 
mechanisms may be considered for the release of drug from 
microparticulates. 
¾ Liberation due to polymer erosion or degradation. 
¾ Self diffusion through the pore. 
¾ Release from the surface of the polymer. 
¾ Pulsed delivery initiated by the application of an  oscillating 
 or sonic field. 
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 In most of the cases, a combination of more than one 
mechanism for drug of release may operate so the distinction 
amongst the mechanisms is not always trivial. The release profile 
from the microspheres depends on the nature of the polymer used 
in the preparation as well as nature of the active drug. The release 
of drug from both biodegradable as well as non biodegradable 
microspheres is influenced by structure or micro- morphology of 
the carrier and the properties of the polymer itself. 
  
 Factors affecting the release of the drug from the particulate 
system in relation to drug, microspheres and bioenvironment: 
¾ Drug 
¾ Position in microspheres 
¾ Molecular weight 
¾ Physicochemical properties 
¾ Concentration 
¾ Interaction with matrix 
¾ Microspheres 
¾ Type and amount of polymer 
¾ Size and density of the microspheres 
¾ Extent of cross linking, denaturation or polymerization 
¾ Environment 
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¾ pH 
¾ Polarity 
¾ Presence of enzyme 
RESERVOIR TYPE SYSTEM 
 Release from the reservoir type system with rate controlling 
membrane proceeds by first penetration of the water through the 
membrane followed by dissolution of the drug in the penetrating 
dissolution fluid. The dissolved drug after partitioning through the 
membrane diffuses across the stagnant diffusion layer. The release 
is essentially governed by the Fick’s first law of diffusion as 
          J=-D (dc/dx) 
 Where, J is flux per unit area 
 D = diffusion coefficient 
 (dc/dx) = concentration gradient 
 Diffusion across the membrane determines the effectiveness 
of the carrier system. The cumulative amount of drug that is 
released through the unit area, ‘Qt’ at any time ‘t’ is given by 
equation: 
 Qt = CsKDmDdt/KDmIm+DdId 
 Where, Cs = saturation solubility of drug in dispersion 
medium 
 Dm = diffusion coefficient of drug in membrane of thickness 
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Im 
 Dd = diffusion coefficient of drug in static diffusion layer of 
thickness Id 
 K = partition coefficient of drug between membrane and 
reservoir compartments. 
 The release rate from the carriers can be modified by 
changing both the composition and the thickness of the polymeric 
membrane. 
MATRIX TYPE SYSTEM 
 Release profile of the drug from the matrix type of the device 
critically depends on the state of drug whether it is dissolved or 
dispersed in the polymer matrix. In case of the drug dissolved in 
the polymeric matrix, amount of drug, and the nature of the 
polymer (whether hydrophobic or hydrophilic) affect the release 
profile. 
       In case of drug dissolved in the polymeric matrix, the amount 
of drug appearing in the receptor phase at time‘t’ is approximated 
by two separate equations. The first equation determines the initial 
60 percent of the drug release while the second shows the release 
profile at the later stage. 
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Fig.No.3 :  Schematic Representation of Controlled Drug 
Molecules from a Matrix type drug delivery devices 
 dMt/dt = 2Mx(D/πl2t)t/2 
         dMt/dt =8DMx/l2expπ2Dt/l2 
  Where, l = thickness of polymer slab 
 D = diffusion coefficient 
 Mx = total amount of the drug present in the matrix 
 Mt = amount of the drug released in time t 
         When the drug is dispersed throughout the polymer matrix 
then the release profile follows Higuchi’s equation: 
         dMt/dt=A/2(2DCsCo)l/2/t 
 Where, A = area of matrix 
 Cs = solubility of the drug in the matrix 
 Co = total concentration in the matrix. 
 Taking porosity (ε) and tortuosity (г) of the matrix into the 
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consideration the above equation can be rewritten as  dMt/dt = [ 
ε/г Dm(2Co-εCs)Cst]l/2 
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POLYMER PROFILE 
 
POLY (ε-CAPROLACTONE)35,36 
 
General introduction  
  Poly (ε- caprolactone) (PCL) is a semicrystalline polyester 
biodegradable polymer which comes under the category of aliphatic 
polyester. Aliphatic polyesters are a group of synthesized, nontoxic, 
biodegradable polymers. They are synthetic homopolymers or 
copolymers of lactic acid, glycolic acid and ε-hydroxycaproic acid. 
Polycaprolactone (PCL) is of great interest as it can be obtained by 
the ROP of a relatively cheap monomeric unit ‘e-caprolactone’. The 
PCL is highly processible as it is soluble in a wide range of organic 
solvents while having the ability to form miscible blends with wide 
range of polymers. Typically, the molecular weights of 
homopolymers and co-polymers range from 2000 to >100000. 
             The rate of biodegradation and drug-release characteristics 
from these systems formulated with the aliphatic polyesters can be 
controlled by changing the physicochemical properties of the 
polymers, such as crystallinity, hydrophobicity, monomer 
stereochemistry, co-polymer ratio, and polymer molecular weight. 
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Synonym  
 PCL 
Chemical name 
  2- oxypanone 
Chemistry  
            Structure :   
 
Description  
Molecular weight :        80 – 150000 
Melting point                           :        58 – 63˚C 
Glass transition temperature :        -65 to -60˚C 
Colour :       White 
Solubility :         dichloromethane, chloroform, 
    
Specific gravity                        :        1.11 
Tensile strength                      :          3000 – 5000psi 
Elongation (%) :           300 – 500% 
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Modulus (Psi)                          :            3 – 5 × 107psi 
FUNCTIONAL CATEGORY 
 Bioabsorbable, biocompatible, biodegradable material 
STABILITY AND STORAGE CONDITIONS 
 The aliphatic polyesters are easily susceptible to hydrolysis 
in the presence of moisture. Hence they should be properly stored, 
preferably refrigerated at below 0˚C. It is necessary to allow the 
polymers to each room temperature before opening the containers. 
After the original package has been opened, it is recommended to 
re-purge the package with high purity dry nitrogen prior to 
resealing. 
APPLICATIONS IN PHARMACEUTICAL FORMULATION OR 
TECHNOLOGY 
 Aliphatic polyesters are a group of synthesized, non 
toxic, biodegradable polymers. In an aqueous environment, 
they undergo hydrolytic degradation, through cleavage of 
the ester linkages, into non toxic hydroxyl carboxylic acids. 
Aliphatic polyesters are eventually metabolized to 
carbondioxide and water, via the citric acid cycle. As  the 
polymer undergoes hydrolytic degradation due to the 
presence of hydrolytically labile aliphatic ester linkages; 
however, the rate of degradation is rather slow (2–3 years). 
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Due to the slow degradation, high permeability to many 
drugs and non-toxicity, PCL was initially investigated as a 
long-term drug/vaccine delivery vehicle. Owing to their 
reputation as safe materials and their biodegradability, 
aliphatic polyesters are primarily used as biocompatible 
and biodegradable polymers for formulation of many types 
of implantable and injectable drug delivery systems for both 
human and vetenary use. Examples of implantable drug 
delivery systems include rods, cylinders, tubing, films, 
fibres, pellets and beads. Examples of injectable drug 
delivery system include microcapsules, microspheres, 
nanoparticles and liquid injectable controlled release 
systems. The rate of biodegradation and drug release 
characteristics from these systems formulated with the 
aliphatic polyesters can be controlled by changing the 
physicochemical properties of the polymers such as 
crystallinity, hydrophobicity, monomer stereochemistry, 
copolymer ratio and polymer molecular weight. The long-
term contraceptive device Capronors is composed of this 
polymer and has been developed for the long-term zero 
order release of levonorgestrel. PCL has low tensile strength 
(approximately 23MPa) but an extremely high elongation at 
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breakage (4700%).Extensive research is ongoing to develop 
various micro- and nano-sized drug delivery vehicles based 
on PCL. Due to its excellent biocompatibility, PCL has also 
been extensively investigated as scaffolds for tissue 
engineering. A recent study demonstrated the feasibility of 
using a composite matrix composed of PCL and hyaluronic 
acid as a potential meniscus substitute. Composites of PCL 
with calcium phosphate based ceramics are also currently 
being investigated as suitable scaffolds for bone tissue 
engineering. 
Safety  
 Poly(ε-caprolactone) is used in parentral pharmaceutical 
formulations and are regarded as biodegradable, biocompatible and 
bioabsorbable materials. Their biodegradation products are non 
toxic, non carcinogenic and non teratogenic. In general, these 
polyesters exhibit very little hazard. 
Handling precautions 
 Observe normal precautions appropriate to circumstances 
and quantity of material handled. Contact with eyes, skin and 
clothing, and breathing the dust of the polymers should be 
avoided. Aliphatic polyesters produce acid materials such as 
hydroxyacetic and/ or lactic acid in presence of moisture; thus, 
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contact with materials that will react with acids, especially in moist 
condition should be avoided. 
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DRUG PROFILE 
DILTIAZEM HYDROCHLORIDE32-34 
 Diltiazem hydrochloride is a member of the group of drugs 
known as benzothiazepines, which are a class of calcium channel 
blockers. 
Chemical name 
 Cis-(+)-[2-(2-dimethylaminoethyl)-5-(4-methoxyphenyl)-3-
oxo-6-thia-2-azabicyclo[5.4.0]undeca-7,9,11-trien-4-yl]ethanoate 
Empirical formula 
C22H26N2O4S.Hcl 
    Chemical structure 
.Hcl 
 
 
Description  
Colour :  White  
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Solubility :  Freely soluble in water, methanol, 
chloroform, slightly soluble in                       
ethanol, insoluble in benzene                
Melting point :  207.5-212˚C 
Molecular weight :  450.98 
Half life :  3-4.5 hrs 
Dosing information 
¾ Adults  
          In atrial arrhythmia an IV bolus, initial  0.25 mg/kg (or 20            
mg) IV over 2 min and IV continuous infusion, initial 5-10 mg/hr; 
increase in 5 mg/hr increments up to 15 mg/hr maintained for  
up to 24 hr. 
          In hypertension, Sustained  release  initial 60-120 mg orally 
twice daily; usual dose 120-180 mg twice daily, maximum 360 
mg/day. Extended release initial 120-240 mg orally once daily: 
titrate after 14 days: usual dose, 240-360 mg orally once daily, 
maximum 540 mg/day 
¾ Pediatric  
          Not FDA- approved in pediatric patients. 
 
MECHANISM 
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• Diltiazem is a potent vasodilator, increasing blood flow and 
variably decreasing the heart rate via strong depression of A-
V node conduction. Its pharmacological activity is somewhat 
similar to verapamil.  
• Potent vasodilator of coronary vessels. 
• Vasodilator of peripheral vessels. This reduces peripheral 
resistance and afterload. 
• Negative inotropic effect. Diltiazem causes a modest decrease 
in heart muscle contractility and reduces myocardium 
oxygen consumption. 
• Negative chronotropic effect. Diltiazem causes a modest 
lowering of heart rate. This effect is due to slowing of the SA 
(sinoatrial) node. It results in reduced myocardium oxygen 
consumption. 
• Negative dromotropic effect. By slowing conduction through 
the AV (atrioventricular) node, diltiazem increases the time 
needed for each beat. This results in reduced myocardium 
oxygen consumption by the body. 
Nontherapeutic effects and toxicities 
 Reflex sympathetic response. Caused by the peripheral 
dilation of vessels and the resulting drop in BP; the response works 
to counteract the inotropic, chronotropic and dromotropic effects of 
diltiazem. Symptoms include hypotension, bradycardia, dizziness, 
flushing. 
Chapter 7  Results  & 
Discussion 
 45 
Contraindications and precautions 
¾ Congestive heart failure. Patients with reduced ventricular 
function may not be able to counteract the inotropic and 
chronotropic effects of diltiazem, the result being an even 
higher compromise of function. 
¾ SA node or AV conduction disturbances. Use of diltiazem 
should be avoided in patients with SA or AV nodal 
abnormalities, because of its negative chronotropic and 
dromotropic effects Low blood pressure. Patients with 
systolic blood pressures below 90 mm Hg should not be 
treated with diltiazem. 
¾ Wolff-Parkinson-White syndrome. Diltiazem may 
paradoxically increase ventricular rate in patients with WPW 
syndrome because of accessory conduction pathways. 
¾ Diltiazem is relatively contraindicated in the presence of sick 
sinus syndrome, atrioventricular node conduction 
disturbances, bradycardia, impaired left ventricle function, 
peripheral artery occlusive disease, chronic obstructive 
pulmonary disease, and Prinzmetal's angina. 
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PHARMACOKINETIC PROPERTIES 
Absorption  
 90% administered dose is absorbed but extensive first pass 
metabolism limits the absolute bioavailability to 30-40%. Relative 
to an intravenous dose large patient-to-patient variation in the 
plasma levels achieved with a single oral dose, consistent with a 
large first-pass metabolism or individual differences in absorption. 
Distribution  
¾ Distribution sites 
 Protein binding : 77% to 93% where diltiazem hydrochloride 
binds with albumin in the range of 35 to 40%.Protein binding 
is independent of serum diltiazem hydrochloride 
concentrations and therapeutic serum levels of digoxin, 
hydrochlorthiazide, phenylbutazone, propranolol, salicylic 
acid and warfarin do not influence the percentage of 
unbound diltiazem. 
¾ Distribution kinetics 
 Distribution half-life : 0.3 hours 
 Volume of distribution: 5.3L/kg (300 to 400 litres) 
Metabolism  
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 DTZ  primarily gets metabolized in liver through 
deacetylation. The metabolites of DTZ are Deacetyl diltiazem 
(active)  which is the major metabolite; present in the plasma at 
levels of 10% to  45% of the parent; 25% to 50% as a potent 
coronary  vasodilator and N-monodesmethyldiltiazem (inactive) 
which accumulates more than desacetyldiltiazem at steady state. 
Excretion  
¾ 35% of DTZ undergoes Renal excretion. Only 1% to 3% as 
unchanged diltiazem, the bulk as metabolites. Total body 
clearance : 11.8 mL/minute/kg(2 fold decrease after 
repeated dose). Value may be up to 2-fold lower after 
repeated dosing. 
Elimination half-life 
 For parent compound elimination half- life was 3.06 to 6.6 
 hours and for extended release formulation 4 to 10 hours. All 
extended or controlled release dosage forms report similar ranges 
(4 to 9.5; 5 to 7;5 to 10 hours) of apparent half-life following both 
single and multiple doses. Half-life of diltiazem long acting tablets 
is 6 to 9 hours. 
 PRECAUTIONS  
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 Coadministration with other drugs known to decrease 
peripheral resistance, intravascular volume or myocardial 
contractility or conduction. 
 Concomitant use of beta blockers or digitalis; additive effect 
on heart rate. 
 Dermatologic reactions leading to erythema multiforme 
and/or exfoliative dermatitis. 
 Hepatic impairment; increased risk of toxicity. 
 Hypotension  
 Renal impairment; increased risk of toxicity. 
 Supraventricular arrhythmias with hemodynamic 
compromise. 
 Ventricular function impaired; worsening congestive heart 
failure. 
ADVERSE EFFECTS 
¾ Mild adverse effects 
 Allergic reactions :  Skin rash, hives, itching  
 Other reaction :  Headache, drowsiness,  dizziness,  
  nervousness, depression, confusion,  
  hallucination 
¾ Severe adverse effects 
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 Asystole, bradyarrhythmia. Cardiac disrhythmia, congestive 
heart failure, edema, heart block, vasculitis, hypotension, 
myocardial infarction. 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 S.Jayaprakash et al.,8 (2009), in their work “Preparation 
and evaluation of biodegradable microspheres of Methotrexate” 
reported that sustained release methotrexate microspheres of 
bovine serum albumin were prepared in different ratios by 
emulsion cross linking method. The prepared microspheres were 
subjected to various physicochemical evaluation and in-vitro 
release studies. The drug release from microspheres of 1:6 ratio 
was found with most constant and prolonged drug release and it 
follows diffusion by erosion mechanism. The characteristics of 
prepared microspheres are conductive to the formulation of the 
sustained release drug delivery system.  
 Yodthong Baimark et al.,9 (2009), in their work 
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“Preparation of organic  solvent/ surfactant free microspheres 
of methoxy poly(ethylene glycol)-b-poly(ε-caprolactone) by a 
melt dispersion method” reported that the microspheres were 
produced in 90-100°C glycerol by melt dispersion method. 
Morphology of the microspheres was spherical in shape with rough 
surfaces. Almost microspheres were in the size range of  
300-500 μm. Microsphere cross-sections showed condensed 
phases throughout the microsphere matrices. Melting 
temperatures and heats of melting of the MPEG-b-PCL were 
decreased in the microsphere form. In conclusion, the use of melt 
dispersion method results in organic solvent and surfactant-free 
biodegradable microspheres of diblock copolymer that showing a 
potentially useful drug delivery systems with free from surfactants 
and organic solvents. 
 Nazar Mohammad Ranjha et al.,10 (2009), in their work  
“Encapsulation and characterization of Flubiprofen loaded 
poly(ε-caprolactone)-poly(vinylpyrollidone) blend microspheres 
by solvent evaporation method” reported that  Flurbiprofen 
loaded PCL/PVP blend microspheres were prepared by o/w solvent 
evaporation method. Microsphere recovery decreased with a 
decrease in the concentration of the emulsifier in the dispersion. 
Encapsulation efficiency and drug loading of microspheres 
increased with decrease in concentration of emulsifying agent. 
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Hydration rate, encapsulation efficiency and drug loading of 
microspheres increased with increase in concentration of PVP. SEM 
photographs revealed microspheres were discrete, spherical and 
became porous with decrease in concentration of emulsifying agent 
and vice versa. FTIR spectra of pure and encapsulated flurbiprofen 
in all formulation showed no significant difference in characteristic 
peaks, suggesting stability of flurbiprofen during encapsulation 
process. X-RD (X-ray powder diffractometry) of pure flurbiprofen 
shows sharp peaks, which decreases on encapsulation, indicating 
dispersion at molecular level and hence decrease in the 
crystallinity of drug in microspheres. Microspheres had shown an 
enteric nature at pH 1.2 and a sustained release pattern at pH 6.8. 
Rapid drug release was observed in microspheres with higher 
concentration of PVP (polyvinylpyrrolidone). Drug release kinetics 
followed zero order at pH 1.2 while at pH 6.8 Higuchi model was 
best fitted and was found non fickian.  
 Jeevana J.B et al.,11(2009), in their work “ Development 
and Evaluation of Gelatin microspheres of Tramadol 
Hydrochloride” reported that Tramadol hydrochloride could be 
encapsulated into gelatin microspheres with an entrapment 
efficiency of 97.2%. Spherical, transparent and free flowing 
microspheres were obtained. SEM revealed the spherical 
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structures. The FTIR and DSC analysis indicated the stability and 
compatibility of the drug in gelatin microspheres. The microspheres 
were in the suitable particle size range of 20-160µm. the drug was 
released continuously for a period of 12 hrs with a maximum 
release of 99.79%. 
 S.Thamizharasi et al.,12 (2008), in their work “Formulation 
and evaluation of Pentoxyfylline loaded poly (e-caprolactone) 
microspheres” reported that  pentoxyfylline loaded poly(ε-
caprolactone) microspheres were prepared by solvent evaporation 
technique with different drug to carrier ratio [(1:3), (1:4), (1:5) and 
(1:6)]. The shape of microspheres were found to be spherical [SEM]. 
The size of microspheres were found to be ranging 59.3±6.3µm to 
86.22±4.23µm. Among the four drug to carrier ratio 1:6 showed 
maximum percentage yield and 1:4 showed highest drug 
entrapment. The release followed Higuchi kinetics indicating 
diffusion controlled drug release. 
 S. Ravi et al.,13 (2008), in their work “Development and 
characterization of polymeric microspheres for controlled 
release protein loaded drug delivery system” reported that the 
hydrophilic bovine serum albumin was chosen as a model protein 
to be encapsulated with poly (D,L-lactide-co-glycolide) ( 50:50) 
microspheres using a w/o/w double emulsion solvent evaporation 
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method. The microspheres prepared with different molecular 
weight and hydrophilicity of poly (D,L-lactide-co-glycolide) were 
found to be non porous smooth surfaced and spherical in structure 
under SEM with a mean particle size ranging from 3.98 to 8.74µm. 
The protein loading efficiency varied from 40 to 71℅ of the 
theoretical amount incorporated. The in vitro release profile of 
bovine serum albumin from microspheres presented two phases, 
initial burst release phase due to the protein absorbed on 
microsphere surface, followed by slower and continuous release 
phase corresponding to the protein entrapped in polymer matrix. 
 Parasuram Rajam Radhika et al.,14 (2008), in their work 
“Preparation and evaluation of delayed release Aceclofenac 
microspheres” reported that delayed release microspheres of 
aceclofenac were formulated using an enteric polymer, cellulose 
acetate phthalate (CAP) prepared by solvent evaporation technique. 
The effects of various other modern enteric polymers such as 
hydroxyl propyl methyl phthalate cellulose (HPMCP), eudragit L 
100 and eudragit S100 on the release of aceclofenac from the CAP 
microspheres have been evaluated. The microspheres were 
characterized for particle size, scanning electron microscopy(SEM), 
percentage yield, drug entrapment and in vitro release kinetics. The 
shape of microspheres were found to be spherical. The drug 
entrapment efficiency of microspheres was found to be ranging 
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from 75.65 to 96.52%w/w. The results also revealed that HPMCP 
exhibits positive influence where as eudragit L 100 and eudragit S 
100 exhibits negative effect on the drug release rate of CAP 
microspheres. In-vitro drug release from all formulations followed 
the first order release kinetics and erosion plot. 
 A.V.Yadav et al.,15 (2008), in their work “Development of 
biodegradable starch microspheres for intra nasal delivery” 
reported that spherical microspheres were obtained in all batches 
with mean diameter in the range of above 22.8 to 102.63µm. They 
showed a good mucoadhesive property and swelling behavior. The 
in-vitro release was fond in the range of 73.11-86.21%w/w. 
Concentration of both polymer and drug affect in-vitro release of 
drug from the microspheres. 
 Rima Kassab et al.,16 (2008), in their work “Formulation of 
Modified Microspheres Based on Cyclodextrin-Lactic Acid 
Polymers” reported that Polymers, based on Poly L-lactic acid (L-
PLA) and coupled with β-Cyclodextrin (β-CD), have been used for 
the preparation of microspheres for drug encapsulation. The 
strategy was based on the modification of the terminal carboxylic 
group of L-PLA (73.000) by coupling it with a β-CD in the presence 
of the peptide coupling agents: DCC/HOBT. The degree of 
functionalisation was found to be 80%. Characterizations of the 
new product were carried out using 1H NMR, gel permeation 
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chromatography, and acid base titration. The size of the 
functionalized microspheres were determined to be 211 μm by 
Dynamic Light Scattering (DLS). Amphotericin B (AmB), a polyenic 
antifungal molecule, has been incorporated in L-PLA coupled with 
β-CD microspheres. The maximal quantity of AmB encapsulated, 
reported to 100 mg of the microspheres, was 7.2 mg with an 
encapsulation ratio of 60%. 
 Hetal Paresh Thakkar et al.,17 (2008), in their work  
“Effect of crosslinking agent on the characteristics of 
Celecoxib loaded chitosan microspheres” reported that chitosan 
microspheres were prepared by emulsification cross linking 
method. The entrapment efficiency of glutaraldehyde and 
formaldehyde cross-linked microspheres were significantly higher 
(p<0.05) than heat cross-linked microspheres. In-vitro drug release 
studies indicated that the microspheres cross linked using 
gluteraldehyde showed slower release rate than those cross linked 
with formaldehyde while the heat cross-linked microspheres 
showed the fastest release. 
 M.Nappinai. et al.,18 (2007), in their work “Formulation 
and evaluation of microspheres of Diltiazem hydrochloride” 
reported that microspheres of diltiazem hydrochloride were 
formulated using combination of poly ethylene glycol 6000 and 
eudragit RS 100 and eudragit RS 100 alone by solvent evaporation 
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and non solvent addition methods with an aim to prolong its 
action. Formulation prepared using the combination of the 
retardants exhibited first order of drug release and zero order for 
preparation containing eudrajit RS alone. 
 A.Mukherjee et al.,19 (2007), in their work “Preparation 
and characterization of poly-ε-caprolactone particles for 
controlled Insulin delivery” reported that the method was for the 
efficient encapsulation of insulin in poly-ε-caprolactone 
microspheres and nanospheres using a water-in-oil-in-water 
double emulsion solvent evaporation method. The microspheres 
and nanospheres formed were characterized for entrapment 
efficiency, percentage yield, particle size analysis, morphological 
characteristics and the drug release profiles. The  studies revealed 
a successful formulation of smooth spherical poly-ε-caprolactone 
microspheres and nanospheres encapsulating insulin, thus 
highlighting them as potential controlled drug delivery systems. 
 D.M Morkhade et al.,20 (2007), in their work “ Evaluation 
of gum dammar as a novel microencapsulating material for 
Ibuprofen and Diltiazem hydrochloride” reported that 
microparticles were prepared by oil-in-oil emulsion solvent 
evaporation method. The effect of different gum : drug ratios and 
solubility of drug on microparticle properties was principally 
investigated. With diltiazem hydrochloride, gum dammar produced 
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bigger (40-50µm) and fast drug releasing microparticles with low 
encapsulation efficiencies(44-57℅). Contrary, with ibuprofen, gum 
dammar produced small (24-33µm) microparticles with better drug 
encapsulation (85-91℅) and sustained drug delivery. The increase 
in gum: drug ratio had shown an increase in particle size, 
encapsulation efficiency and decrease in drug release rate in all 
cases. 
 Shaobing Wang et al.,21 (2007), in their work “Disodium 
norcantharidate loaded poly(ε-caprolactone) microspheres: 
preparation and evaluation” reported that Poly( -caprolactone) 
(PCL) microspheres encapsulating disodium norcantharidate 
(DSNC), a drug in salt form and with high water solubility, were 
prepared by s/o/w solvent evaporation technique and 
characterized in terms of size, morphology, encapsulation efficiency 
and drug release. The viscosity of s/o dispersion was crucial to the 
successful encapsulation of DSNC.  Scanning electron microscopy 
(SEM) studies had shown that the drug-loaded microspheres had 
coarse surface and porous internal structure. The analysis of X-ray 
diffraction (XRD) indicated that there was no interaction between 
DSNC and PCL, but the degree of crystallinity of PCL decreased 
with the introduction of the drug. The drug release profiles 
indicated an initial burst release followed by a slow release, and a 
further investigation into the release mechanism implied that the 
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release of DSNC from PCL microspheres was caused by a 
combination of diffusion and osmotic pressure. 
 Mundargi R.C et al.,22 (2007), in their work “Development 
and evaluation of novel biodegradable microspheres based on 
poly(d,l-lactide-co-glycolide) and poly(epsilon-caprolactone) for 
controlled delivery of doxycycline in the treatment of human 
periodontal pocket: in-vitro and in-vivo studies” reported that 
development of novel biodegradable microspheres prepared by 
water-in-oil-water (W/O/W) double emulsion technique using the 
blends of poly(d,l-lactide-co-glycolide) (PLGA) and poly(epsilon-
caprolactone) (PCL) in different ratios for the controlled delivery of 
doxycycline (DXY). Doxycycline encapsulation of up to 24% was 
achieved within the polymeric microspheres. Blend placebo 
microspheres, drug-loaded microspheres and pristine DXY were 
analyzed by Fourier transform FT-IR, which indicated no 
interaction between drug and polymers. DSC on drug-loaded 
microspheres confirmed the polymorphism of DXY. SEM confirmed 
the spherical nature and smooth surfaces of the microspheres 
produced. In-vitro release studies performed in 7.4 pH media 
indicated the release of DXY from 7 to 11 days, depending upon the 
blend ratio of the matrix. Up to 11 days, DXY concentrations in the 
gingival crevicular fluid were higher than the minimum inhibitory 
concentration of DXY against most of the periodontal pathogens. 
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One of the developed formulations was subjected to in vivo efficacy 
studies in thirty sites of human periodontal pockets. 
 Xudong Wang et al.,23 (2006), in their work “Drug 
distribution within poly (ε-caprolactone) microspheres and in 
vitro release” reported that Poly( -caprolactone) (PCL) 
microspheres loaded with two model compounds (p-nitroaniline 
and rhodamine B) with different water solubilities were prepared by 
an s/o/w single emulsion solvent evaporation method. The 
microspheres morphology were investigated by SEM, drug loading 
and encapsulation efficiency were also calculated. Drug 
distribution within microsphere matrix was studied by confocal 
laser scanning microscopy. p-Nitroaniline, as a more hydrophobic 
compound, distributed more evenly in the matrix, while the more 
hydrophilic compound rhodamine distributed close to the surfaces 
of microspheres. The in-vitro release profiles therefore were 
different. This study helps to further understand the drug release 
mechanism from microsphere matrix, and design effective long-
term drug delivery system. 
 Bhalero S.S et al.,l24 (2003), in their work “Study of 
processing parameters influencing the properties of Diltiazem 
hydrochloride microspheres” reported that prepared diltiazem 
hydrochloride- ethyl cellulose microspheres by water- in- oil 
emulsion solvent evaporation technique produced small and 
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spherical microspheres having a mean microsphere diameter in the 
range of 40-300µm and entrapment efficiency of 60-90℅ were 
obtained. The in-vitro release profile could be altered significantly 
by changing various processing parameters to give a controlled 
release of drug from the microspheres. The stability studies of the 
drug- loaded microspheres showed that drug was stable at storage 
temperatures, 5-55˚C, for 12 weeks. 
 J.L.Maia et al.,25 (2003), in their work “The effect of some 
processing conditions on the characteristics of biodegradable 
microspheres obtained by emulsion solvent evaporation 
process” reported that unloaded microspheres were prepared from 
polyhydroxybutyrate (PHB) and polyhydroxybutyrate-co-valerate 
(PHB-HV) polymers using an oil-in-water emulsion solvent 
evaporation method. The study was conducted to evaluate how the 
polymer and some process parameters affect properties of the final 
microspheres such as particle size, superficial area, zeta potential, 
surface morphology and microsphere degradation. The variables 
included surfactant concentration in the emulsion water phase and 
solvent composition. From the results, it was found that the 
parameters affecting microsphere size the most were surfactant 
concentration in the emulsion’s water phase and solvent 
composition. Properties such as zeta potential, surface area and 
surface morphology remained pratically unchanged over the range 
Chapter 7  Results  & 
Discussion 
 61 
of the processing conditions studied here.  
 B.K.Kim et al.,26 (2003), in their work “Characteristics of 
Felodipine- loaded poly (ε-caprolactone microspheres” reported 
that Felodipine-loaded poly (ε-caprolactone) microspheres were 
prepared by two methods that is, the conventional emulsion 
solvent evaporation method and the quenching method. The results 
show that, when conventional emulsion solvent evaporation 
method was u sed, the o/w-method produced smaller mean size 
and higher encapsulation efficiency compared with the w/o-
method. The encapsulation efficiencies increased with an increase 
in the molecular weight and a decrease in crystallinity of PCL. The 
size of microspheres varied with the type of emulsion stabilizer 
used, smaller microspheres with PVA and narrow size distribution 
with Pol 237. When water-soluble solvents such as acetonitrile and 
ethyl formate were used, the encapsulation efficiencies decreased 
due to higher evapouration rate. When quenching methods were 
used, in contrast to the conventional emulsion solvent 
evapouration method, very narrow size-distributed but larger 
microspheres were obtained. 
 Sang – wook Sun et al.,27 (2003), in their work  
“Surfactant free microspheres of poly(ε- caprolactone)/poly 
(ethylene glycol)/poly(ε-caprolactone)  triblock copolymers as a 
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protein carrier” reported that a poly(ε-caprolactone)/ 
poly(ethylene glycol)/poly(ε-caprolactone) (CEC) triblock copolymer 
was synthesized by the ring-opening of ε-caprolactone with 
dihydroxy poly (ethylene glycol) to prepare surfactant-free 
microspheres. When dichloromethane (DCM) or ethyl formate (EF) 
was used as a solvent, the formation of microspheres did not occur. 
Although the microspheres could be formed prior to lyophilization 
under certain conditions, the morphology of microspheres was not 
maintained during the filtration and lyophilization process. 
Surfactant-free microspheres were only formed when ethyl acetate 
(EA) was used as the organic solvent and showed good spherical 
microspheres although the surfaces appeared irregular. The 
content of the protein in the microsphere was lower than expected, 
probably because of the presence of water channels and pores. The 
protein release kinetics showed a burst release until 2 days and 
after that sustained release pattern was showed.  
 D.Vijaya Ramesh et al.,28 (2002), in their work  
“ Microencapsulation of FTIC- BSA into poly(ε- caprolactone) 
by water- in -oil –in-oil solvent evaporation technique” reported  
the encapsulation of protein into poly (ε-caprolactone) 
microspheres. The preparation procedures of microspheres 
preparation were with an aim to get different particle size by 
changing the preparative variables such as polymer concentration, 
volume of internal aqueous phase, homogenization speed and 
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stirring speed of solvent evaporation. The morphological 
characteristics of the particles and release profiles of the labeled 
protein were analysed. In optimum conditions spherical and 
smooth PCL microspheres were obtained with high encapsulation 
efficiency. The particle size were reduced as the concentration of 
the polymer solution reduced. The homogenization speed does not 
show any effect on particle size and entrapment characters. The 
release of FITC-BSA lasted longer as the particle size increased. 
 Aberturas  M.R et al.,29 (2002), in their work 
“Development of a new cyclosporine formulation based on 
poly(caprolactone) microspheres” reported that the study 
describes the development of a new cyclosporine formulation based 
on polycaprolactone (PCL) microspheres (MS) prepared by the 
solvent evaporation method. Ternary phase diagrams were used to 
identify the domains where MS were formed. The application of 
central composite designs established the influence of several 
technological (stirring speed) and formulation factors (polymer and 
surfactant amounts, and organic solvent volume) on the size of PCL 
MS. The experimental design had shown that the stirring speed 
and the organic phase volume were the only parameters 
significantly affecting the MS size. Experimental conditions selected 
to obtain CyA-loaded MS of 2.5 μm resulted in a high entrapment 
percentage (98.4 ± 0.66%), with the drug dissolved or molecularly 
dispersed within the dense polymeric matrix of MS. After 12 
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months of storage at 8 °C and RT, PCL MS remained physically 
stable, although the crystallinity of the polymer increased by 35% 
upon storage at both temperatures. Freeze-drying studies revealed 
that MS could be successfully lyophilized in the absence of 
cryoprotectants without significant changes of the drug 
entrapment. Therefore, a stable MS-based CyA formulation was 
easily prepared and characterized. This formulation offer the 
possibility of CyA administration through different routes. 
 Arica B et al.,30 (2002), in their work “Biodegradable 
bromocryptine mesylate microspheres prepared by a solvent 
evaporation technique. I: Evaluation of formulation variables 
on microspheres characteristics for brain delivery” reported 
that the effect of formulation parameters (e.g. polymer, emulsifying 
agent type and concentration) on the characteristics of the 
microspheres produced, the efficiency of drug encapsulation, the 
particle size distribution and in-vitro drug release rates from the 
bromocryptine mesylate microspheres were investigated using a 
3(2) factorial design. Bromocryptine mesylate was encapsulated 
into biodegradable polymers using the following three different 
polymers; poly(L-lactide), poly(D,L-lactide) and poly(D,L-lactide-co-
glycolide). The SEM photomicrographs had shown that the 
morphology of the microspheres greatly depended on the polymer 
and emulsifying agent. The results indicate that, regardless of the 
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polymer type, increase in emulsifying agent concentration from 
0.25-0.75% w/v markedly decreases the particle size of the 
microspheres. Determination of particle size revealed that the use 
of 0.75% w/v of emulsifying agent concentration and a polymer 
solution concentration of 10% w/v resulted in optimum particle 
size. Polymer type has a less pronounced effect on the percentage 
encapsulation efficiency and particle size of microspheres. 
 
 Tomaz Kriczka et al.,l31 (1999), in their work “Kinetics of 
a nucleoside release from lactone-caprolactone and lactide-
glycolide polymers in vitro” reported that the rate of release of a 
model nucleoside (adenosine, 5%, w/w) from nine different lactide-
glycolide or lactide-caprolactone polymers. The polymer discs were 
eluted every second day with an artificial cerebrospinal fluid at the 
elution rate roughly approximating the brain extracellular fluid 
formation rate. Adenosine in eluate samples were assayed by 
HPLC. Three polymers exhibited a relatively constant release of 
adenosine for over four weeks, resulting in micromolar 
concentrations of nucleoside in the eluate. This points to the 
neccessity of further development of polymers of this types as 
intracerebral nucleoside delivery systems for local treatment of 
brain tumors. 
 M.A.Bayomi et al.,32 (1998), in their work “ Preparation of 
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casein- chitosan microspheres containing Diltiazem 
hydrochloride by an aqueous coacervation technique” reported 
that Sustained release microspheres  were prepared with colloidal 
coacervation technique in a completely aqueous environment. The 
entrapment efficiencies of the microspheres were variables (14.5–
53.7%) and depends on the preparation conditions.. The 
dissolution profiles of drug from casein–chitosan microspheres 
showed retarded release pattern of the drug in distilled water. 
Casein and chitosan concentrations, initial drug concentration and 
stirring time were found to be the main parameters that affect the 
properties and the performance of the prepared microspheres. The 
retarded release of DTZ was increased by increasing casein 
concentration, and stirring time. On the other hand, increasing 
chitosan concentration and using high initial drug loading showed 
a fast drug release. 
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SCOPE  OF THE WORK 
 Treatment for an ailment by the physician mostly involved 
drug substances. The use of drug substances had become 
inevitable in the modern days. The major problem faced by the 
patients in taking the medications are to be overcome by altering  
the design of dosage form or properties of the drug moiety.  
        The scope of any formulation primarily focuses on safety and 
efficacy of the drug delivery system. Now the focus has been 
slightly moved to the patient’s convenience and acceptance, where 
still the safety and efficacy remain integrated with design. 
        There are many disorders and diseases that can be treated to 
obtain the better patient outcomes only when the drugs are being 
properly taken. Eg: Diabetes, hypertension requires regular 
monitoring of the respective parameters. The patients find difficult 
being fully compliance to the given prescription. The reasons may 
vary from mainly the frequency of dosing, ease of administration 
including route etc. 
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        Some of the drugs may not be available in the therapeutic 
level or not well absorbed ( low availability or eliminated rapidly 
from the body )and those drugs can be comfortably converted to a 
sustained release or controlled release drug delivery system to 
provide a better patient comfort in terms of acceptance and 
convenience. 
        The previous section of this discussion ( introduction and 
literature survey) had given us a deep insight of the advantages, 
disadvantages and design of the controlled drug delivery systems. 
It also gives on the possibility of converting diltiazem hydrochloride 
(model drug) into a controlled release drug delivery system. The 
drug has poor bioavailability (30%-40%) which in because of large 
amount of drugs undergoes first pass metabolism. The 
bioavailability of the drug can be increased by converting into the 
CRDDS by using poly (ε- caprolactone) a naturally obtained 
biodegradable and biocompatible substances. 
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OBJECTIVE OF THE WORK 
 The main objective of any drug therapy in CRDDS is 
achieving a desired concentration of the drug in plasma or tissue 
which is therapeutically effective for an extended period of time. 
Controlled release system as rapidly emerged over past three 
decades as a new discipline in formulation that offers novel 
approaches to microparticulate dosage forms for bio-active agents, 
so far natural and synthetic polymers were employed to obtain 
control over release pattern of drugs. 
 Diltiazem hydrochloride is a calcium channel blocker, which 
is mainly used in the management of angina pectoris. It was used 
in the present work since it has low bioavailability (30-40%), a dose 
of 30 mg to be taken thrice a day, it has low plasma half life of 3.5 
hr, and undergoes extensive first pass metabolism. To  avoid these 
problem this drug is  formulated into sustained release or 
controlled release dosage forms, which will release the drugs slowly 
into the GIT and maintain the constant drug concentration of the 
drug into the plasma for longer period of time. 
         The use of biodegradable polymers as drug carriers is one of 
the main objectives of recent researchers dealing with long acting 
dosage forms. Of the various biodegradable polymers used for the 
development of sustained release formulations, poly (ε-
caprolactone) has been reported to be advantageous since they are 
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biocompatible. PCL is prepared by ring opening of ε-caprolactone 
using a catalyst such as stannous octanoate. Poly (ε-caprolactone) 
is aliphatic polyester polymer, suitable for controlled drug delivery 
due to high permeability to many drugs and at the same time being 
from toxicity. 
        The basic goal of current study is to develop poly(ε-
caprolactone) microspheres containing the drug diltiazem 
hydrochloride. The poly(ε-caprolactone) microspheres were 
formulated and evaluated with respect to variables like change in 
stirring speed and amount of polymer used. The delivery system 
designed for an oral route of administration where a considerable 
research had been done. Such studies had reported to achieve 
releases either completely or partially. 
 So the current study aimed at design of an oral controlled 
release drug delivery system (micropsheres) for diltiazem 
hydrochloride using poly(ε-caprolactone). 
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PLAN OF WORK 
 The work entitled “Formulation and Evaluation of 
Diltiazem hydrochloride microcapsules for oral controlled 
release drug delivery using poly (ε- caprolactone)” was planned 
and carried out for a period of 9 months ( May 2009- January 
2010) in the following manner. 
Phase I         :    Literature survey 
(May  2009)               Design of the study 
Phase II        :   Preparation of the standard graphs 
 (June -Aug 2009)  Preparation of diltiazem hydrochloride  
  microspheres using poly (ε-caprolactone) 
Phase III       : Evaluation of the prepared microspheres 
(Sept.-Dec. 2009)  • Compatibility studies using IR 
   spectrophotometer 
  • Physical characterization by   
   particle size analysis 
    Scanning electron microscope 
   Optical microscope 
  • Drug content analysis 
    Actual drug loaded into the microspheres 
   in-vitro drug analysis of microspheres 
Phase IV : Data analysis and project submission.  
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(Jan. 2010)  
 
MATERIALS USED 
MATERIALS 
Name of the materials Name of the company 
Diltiazem hydrochloride(gift 
sample) 
Micro labs Ltd, Bangalore 
Poly (ε- caprolactone) ca 
60000  
Hi media biosciences Ltd, 
Mumbai. 
Light liquid paraffin LR Spectrum reagents and chemicals Pvt. Ltd. Edwar, Aluva 
Tween -80 LR Indian research products , Mumbai 
Dichloromethane LR Qualigens Fine chemicals Ltd Mumbai 
Sodium hydroxide AR S .D Fine chemicals Ltd, Mumbai 
Potassium dihydrogen 
monophosphate AR 
S.D.Fine chemicals Ltd, Mumbai 
                                                     
EQUIPMENTS           
Name of equipment Name of  the company 
Optical Microscope and stage 
Micrometer Erma. Japan 
Remi hi-speed motor Universal motors. Mumbai 
UV / Vis Spectrophotometer JASCO V-530. 
Dissolution apparatus Electrolab TDT-08L. Chennai. 
Scanning Electron Microscope JSM6400 
Digital balance Denver instruments 
IR Spectrophotometer Jasco-FT-IR 8201 PC 
pH tester 1 (water proof) Oakton instruments. 
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METHODOLOGY 
PREPARATION OF STANDARD GRAPH FOR DILTIAZEM 
HYDROCHLORIDE 
Preparation of stock solution39 
 100 mg of diltiazem hydrochloride was dissolved in 
phosphate buffer pH 7.4 and the volume was made upto 100 ml in 
a volumetric flask by using phosphate buffer to give 1 mg/ml 
concentration. 
           1ml of the above solution was taken and volume made upto 
100ml by phosphate buffer to give 10µg/ml concentration which 
will be used as a stock solution. The details were given in Table  
No:3. 
Preparation of standard solution 
Table No : 3 Standard solution details 
Test tube 
no 
Stock solution 
(10µg/ml) 
ml 
Phosphate 
buffer 
ml 
Concentration 
(µg/ml) 
           1           0              10             0 
           2           1               9             1 
           3           2                            8             2 
           4           3               7             3 
           5           4               6             4 
           6           5               5             5 
           7           6               4             6 
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           8           7               3             7 
           9           8               2             8 
           10           9               1             9 
           11           10               0             10 
 The absorbance of the above solutions were measured at 
236.5nm (λmax) checked using UV spectrophotometer. Phosphate 
buffer is used as blank. 
 PREPARATION OF POLY(ε-CAPROLACTONE) MICROSPHERES 
 Poly (ε-caprolactone) microspheres were prepared by solvent 
evaporation technique. Accurately weighed quantity of poly (ε-
caprolactone) was dissolved in 10 ml of dichloromethane, then 
200mg of diltiazem hydrochloride was dissolved in this polymer 
phase. This solution was poured in 100ml of liquid paraffin 
containing the emulsifier tween 80 and continuously stirred for 5 
hours. The microspheres were filtered and washed three times with 
50ml of n-hexane and dried at room temperature for 12 hours. 
Microspheres dried at room temperature were then weighed and 
the yield of microspheres prepared were calculated. The variables 
used in this experiment like drug/polymer ratios, striring speed 
ying concentrations of emulsifier and varvaried as given in  
Table No.4. 
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Table No : 4 Composition of different batches of microspheres 
SL 
No 
Formulation 
code 
Drug 
(mg) 
Polymer 
(mg) 
% 
tween 
80 in 
liquid 
paraffin 
Stirring 
speed 
Drug to 
polymer 
ratio 
1 F1 200 200 1.3 500 1:1 
2 F2 200 400 1.3 500 1:2 
3 F3 200 600 1.3 500 1:3 
4 F4 200 8 00 1.3 500 1:4 
5 F5 200 1000 1.3 500 1:5 
6 F6 200 200 1.3 1000 1:1 
7 F7 200 400 1.3 1000 1:2 
8 F8 200 600 1.3 1000 1:3 
9 F9 200 800 1.3 1000 1:4 
10 F10 200 1000 1.3 1000 1:5 
11 F11 200 200 1.3 1500 1:1 
12 F12 200 400 1.3 1500 1:2 
13 F13 200 600 1.3 1500 1:3 
14 F14 200 800 1.3 1500 1:4 
15 F15 200 1000 1.3 1500 1:5 
16 F16 200 200 1.95 500 1:1 
17 F17 200 400 1.95 500 1:2 
18 F18 200 600 1.95 500 1:3 
19 F19 200 800 1.95 500 1:4 
20 F20 200 1000 1.95 500 1:5 
21 F21 200 200 0.65 500 1:1 
22 F22 200 400 0.65 500 1:2 
23 F23 200 600 0.65 500 1:3 
24 F24 200 800 0.65 500 1:4 
25 F25 200 1000 0.65 500 1:5 
26 F26 200 200 0.65 1000 1:1 
27 F27 200 400 0.65 1000 1:2 
28 F28 200 600 0.65 1000 1:3 
29 F29 200 800 0.65 1000 1:4 
30 F30 200 1000 0.65 1000 1:5 
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EVALUATION OF PREPARED MICROSPHERES 
COMPATIBILITY STUDIES 
IR spectral analysis40 
 Weighed amount of the drug (3mg) was mixed with 100mg of 
potassium bromide (dried at 40-50˚C), which was then compressed 
under 10 tonn pressure in a hydraulic press to form a pellet was 
then scanned from 4000-400 cm1 in IR spectrophotometer. 
The same procedure was repeated for various  formulations 
prepared. 
 The IR spectrum of diltiazem hydrochloride drug was 
compared with IR spectrum of the microspheres to understand the 
compatibility. 
PHYSICAL CHARACTERIZATION 
Particle size analysis 
 Scanning Electron Microscope 
 The surface morphology and texture of microcapsules 
prepared were studied by subjecting the samples using  scanning 
electron microscope (SEM). SEM photographs were taken on a 
JSM6400 scanning electron microscope at magnification ranging 
210 to 1700X at room temperature. The microcapsules  were 
sputtered with gold to make the surface conductive before 
scanning. 
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 Optical microscopic method41 
 The particle size distribution analysis was performed by 
using an optical microscope. In this method a slide containing a 
sample of microspheres were dispersed uniformly in liquid paraffin 
and was mounted to assess the particle size distribution by using 
an eye piece micrometer which was calibrated as per the given 
procedure. 
 Standardization of eye piece micrometer42 
 Calibrate the eye piece micrometer with the help of the stage 
micrometer (standard). Note the division of the eye piece 
micrometer scale and stage micrometer scale which coincide with 
each other, use the following formula to assess how much is one 
division of eye piece micrometer. 
One division of stage micrometer= 10µ 
One division of eye piece micrometer 
 =    Number of division of stage micrometer        X 100 
             Number of division of eye piece micrometer 
        After obtaining the required data like frequency of particle in 
each size range (number distribution), various statistical equivalent 
diameters are calculated using the following equations given below 
and in Table No: 5  
p/1
fnd
fpndmean  d
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n =  number of particles in a size range in µm 
d = midpoint in a size range 
p =  an index related to size of an individual particle represents 
if p = 1,2,3 represents length, surface, volume respectively 
p =  positive- arithmetic mean 
p =  negative- arithmetic mean 
p =  zero- geometric mean 
f = 0,1,2, 
Table No  : 5 Statistical Equivalent diameters41 
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Size 
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DRUG CONTENT ANALYSIS 
 The amount of drug loaded was assessed by the following 
methods 
¾ Drug actually loaded into the microspheres 
¾ In-vitro drug release studies 
Drug actually loaded 
          100 mg of diltiazem hydrochloride loaded poly (ε- 
caprolactone) microspheres were crushed with 50ml of phosphate 
buffer. After suitable dilution the absorbance was measured 
UV/Vis spectrophotometer at 236.5nm. Amount of diltiazem 
hydrochloride actually loaded into the microspheres was estimated 
with the help of a standard graph prepared using phosphate buffer 
as blank. 
In-vitro drug release studies 
 Microspheres were kept in an empty hard gelatin capsule 
shell and into apparatus for assessing the drug release pattern. 
Diltiazem hydrochloride release from poly (ε- caprolactone) 
microspheres were investigated in phosphate buffer solution pH 
7.4, using USP dissolution apparatus II, the amount of drug 
release from the microspheres were measured 
spectrophotometrically at 236.5nm using phosphate buffer pH 7.4 
as blank. 
         100 mg of microspheres taken in an empty hard gelatin 
capsule shell was added to 900 ml of phosphate buffer solution in 
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the dissolution apparatus and rotates at 100 rpm/min, the 
temperature of the medium maintained at 37 ± 5˚C for 8 hrs. 
Aliquots of 5ml were withdrawn at specific intervals like  
0hr, .5,1,2,3,4,5,6,7 and 8 hr and analyzed spectrophotometrically 
at 236.5nm after suitable dilution if required. The in-vitro drug 
release profile  obtained by plotting percentage release versus time 
in hours was also done. 
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DISSOLUTION KINETICS OF DRUG RELEASE 43,44 
 To study the release kinetics, data obtained from in-vitro 
drug release studies were plotted in various kinetic models:  
Zero order (Equation 1) as cumulative amount of drug released vs 
time, First order (Equation 2) as log cumulative percentage of drug 
remaining vs time, Higuchi’s model (Equation 3) as cumulative 
percentage of drug released vs square root of time and 
Korsmeyer’s (Equation 4) log cumulative percentage of drug 
released vs. log time 
Zero order 
  C = K0 t.          (Equation1) 
 Where K0 is the zero-order rate constant expressed in units 
of concentration/time and t is the time in hours. A graph of 
concentration vs time would yield a straight line with a slope equal 
to K0 and intercept the origin of the axes. 
First order 
  LogC = LogCo−kt/2:303           (Equation2) 
  Where C0 is the initial concentration of drug, k is the 
first order constant, and t is the time. 
Higuchi’s  
   Q = Kt ½              (Equation3) 
 Where K is the constant reflecting the design variables of the 
system and t is the time in hours. Hence, drug release rate is 
proportional to the reciprocal of the square root of time. 
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 Drug release were plotted in Korsmeyer et al’s equation 
(Equation 4) as log cumulative percentage of drug released vs log 
time, and the exponent n was calculated through the slope of the 
straight line. 
Korsmeyer’s 
   Mt/M∞ = Ktn     (Equation4) 
 Where Mt/M∞ is the fractional solute release, t is the release 
time, K is a kinetic constant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7  Results  & 
Discussion 
 83 
 
 
 
 
RESULTS AND DISCUSSION 
PREPARATION OF STANDARD GRAPHS 
 An attempt was made to confirm the reported λmax  values by 
scanning  the solutions prepared with different solvents of stock 
solution and the  lambda max( λmax) was found as 236.5nm in 
phosphate buffer (pH 7.4). 
            The standard graph for the purpose of estimating the 
amount of drug loaded into the poly (ε-caprolactone) microspheres 
and to assess the amount of drug release in the in-vitro drug 
release samples were done according to the procedure explained in 
the methodology. The results obtained were given in the Table  
No: 6 and Figure.No: 4. 
Table No : 6 Absorbance of Diltiazem hydrochloride in  
phosphate buffer (pH 7.4) 
S.No Concentration (µg/ml) Absorbance at 236.5 nm 
1 0.0 0.0 
2 1.0 0.2022 
3 2.0 0.3103 
4 3.0 0.4681 
5 4.0 0.6410 
6 5.0 0.8136 
7 6.0 0.9498 
8 7.0 1.0911 
9 8.0 1.2899 
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10 9.0 1.4176 
11 10.0 1.5827 
 
Figure 4 : Standard graph of diltiazem hydrochloride with 
phosphate buffer 7.4 
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COMPATIBILITY STUDIES 
IR spectral analysis 
 The microspheres were prepared as discussed earlier in 
methodology with different variables like drug to polymer ratio, 
stirring speed and changing concentration of emulsifier. 
 The obtained micropsheres were subjected to compatibility 
studies  by using an IR spectrophotometer. The IR spectrum 
obtained for DTZ, was compared with the IR spectrum  
of various formulations prepared. The presence of characteristic 
peaks at 3032.51cm-1, 1373.07cm-1, 1743.33cm-1, 1679.69cm-1,  
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689.427cm-1 and 1607.38cm-1  representing the DTZ were also 
found to present in the spectrum of different formulations. 
 The above discussion confirmed that the drug taken was not 
having any interactions with the polymer used. Hence the polymer 
poly (ε-caprolactone) was found to be compatible with the drug 
(DTZ). To confirm any effect on increasing concentration of polymer 
with drug different batches were studied and reports revealed that 
the increase in concentration does not produce any incompatibility 
problem between polymer and drug. 
             The IR spectrum of the individual drug, polymer and for 
selected formulations were given in the following Figure.No: 5-10. 
Fig.No. 5: IR Sepctrum of  Diltiazem Hydrochloride 
 
Fig.No. 6 : IR spectrum of F3 
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Fig.No. 7 : IR spectrum of F8 
 
 
Fig.No. 8: IR spectrum of F18 
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Fig.No. 9: IR spectrum of F23 
 
 
Fig.No. 10: IR spectrum of F28 
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PHYSICAL CHARACTERIZATION 
Optical Microscopy 
 To establish the uniformity in size distribution of the 
prepared microspheres the particle size distribution analysis was 
performed as described in the methodology by using an optical 
microscopy technique. The various mean diameters described were 
also calculated. The results revealed that the size distribution of 
the prepared microspheres were found to be uniform and narrow. 
The above result were also evident from the following normal 
distribution graph obtained while plotting the mean size range and 
number of particles. The graphs obtained were given in the 
following  Figure.No: 11-16. 
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Fig.No. 11: Normal Frequency Distribution curve (F1-F5) 
 
Fig.No. 12: Normal Frequency Distribution Curve (F6-F10) 
 
 
 
 
Fig.No. 13: Normal Frequency Distribution Curve (F11-F15) 
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Fig.No. 14: Normal Frequency Distribution Curve (F16-F20) 
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Fig.No. 15: Normal Frequency Distribution Curve ( F21-F25) 
 
Fig.No. 16: Normal Frequency Distribution Curve ( F26-F30) 
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EFFECT OF CONCENTRATION OF POLYMER 
 The effect of concentration of  polymer on the size of 
microspheres formed were studied and it was found that there was 
an increase in  average diameter of particles as  an increase in the 
concentration of polymer since at higher concentration the polymer 
solution dispersed into larger droplets which can be confirmed 
from the following table no:7. Similar result was observed from 
S.Tamizharasi et al12 where the particle size gradually increased 
with increasing in proportion of PCL. 
EFFECT OF STIRRING SPEED 
 The effect of stirring speed on the size of microspheres were 
studied and  found that there was a decrease in average diameter 
of the particles as the stirring speed increased which was evident 
from the Table.No: 8 given below. In a similar study S.Ravi et al13 
reported that size of the microspheres was determined by the 
stirring speed. Stirring speed was parameter of primary importance 
in the emulsification step because it provides energy to disperse 
the oil phase in aqueous. The mean particle size of the 
microspheres was inversely proportional to stirring speed; 
consequently increase in stirring speed decreased the size of the 
microspheres because secondary emulsion was broken up into 
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smaller droplets at higher input power. But in our study the 
preparation of secondary emusion was not done. 
Table.No. 7:  Average mean diameter of the microspheres  
(F1-F30) 
Conc of 
emulsifier 
(%w/v) 
Stirring 
speed 
(rpm) 
Drug to 
polymer 
ratio 
Code 
Length 
no 
(µm) 
Surface 
no 
(µm) 
Volume 
no 
(µm) 
Volume 
surface 
(µm) 
1:1 F1 49.2 54.415 63.145 85.030 
1:2 F2 50.4 56.683 62.124 74.622 
1:3 F3 52.8 57.31 61.32 70.19 
1:4 F4 53.4 59.47 64.21 74.84 
500 
1:5 F5 55.5 62.426 68.302 81.764 
1:1 F6 52.8 58.40 62.92 73.06 
1:2 F7 54 59.62 64.417 75.1898 
1:3 F8 54.3 60.07 64.87 75.65 
1:4 F9 54.6 61.26 66.506 78.65 
1000 
1:5 F10 57.3 63.42 68.50 79.92 
1:1 F11 44.1 48.652 52.754 62.025 
1:2 F12 47.4 52.564 57.29 68.062 
1:3 F13 49.8 55.23 60.01 70.84 
1:4 F14 51 56.683 61.571 72.647 
1.3 
1500 
1:5 F15 52.2 57.940 62.986 74.437 
1:1 F16 48.3 53.075 57.558 67.692 
1:2 F17 49.8 55.236 60.012 70.841 
1:3 F18 52.5 57.784 62.512 73.160 
1:4 F19 52.5 58.558 63.798 75.728 
1.95 500 
1:5 F20 55.8 61.555 66.649 78.135 
1:1 F21 45.6 50.646 55.466 66.526 
1:2 F22 46.5 52.048 57.189 69.045 
1:3 F23 50.4 56.205 61.345 73.077 
1:4 F24 52.8 58.864 64.068 75.896 
500 
1:5 F25 53.1 58.558 63.274 73.878 
1:1 F26 45.6 51.176 56.415 68.557 
1:2 F27 47.4 53.075 58.342 70.495 
1:3 F28 50.7 57 62.684 75.810 
0.65 
1000 
1:4 F29 51.3 56.683 61.577 72.668 
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  1:5 F30 51 56.365 61.141 71.941 
 
 
 
Table No 8: Average mean diameter of the microspheres with 
respect to stirring speed 
Concentration 
of emulsifier 
(%) 
Drug to 
polymer 
ratio 
Stirring 
speed Code 
Length 
no 
(µm) 
Surface 
no 
(µm) 
Volume 
no 
(µm) 
Volume 
surface 
(µm) 
500 F1 49.2 54.415 63.145 85.030 
1000 F6 52.8 58.40 62.92 73.06 1:1 
1500 F11 44.1 48.652 52.754 62.025 
500 F2 50.4 56.683 62.124 74.622 
1000 F7 54 59.62 64.417 75.1898 1:2 
1500 F12 47.4 52.564 57.29 68.062 
500 F3 52.8 57.31 61.32 70.19 
1000 F8 54.3 60.07 64.87 75.65 1:3 
1500 F13 49.8 55.23 60.01 70.84 
500 F4 53.4 59.47 64.21 74.84 
1000 F9 54.6 61.26 66.506 78.65 1:4 
1500 F14 51 56.683 61.571 72.647 
500 F5 55.5 62.426 68.302 81.764 
1000 F10 57.3 63.42 68.50 79.92 
1.3 
1:5 
1500 F15 52.2 57.940 62.986 74.437 
500 F21 45.6 50.646 55.466 66.526 1:1 
1000 F26 45.6 51.176 56.415 68.557 
500 F22 46.5 52.048 57.189 69.045 1:2 
1000 F27 47.4 53.075 58.342 70.495 
500 F23 50.4 56.205 61.345 73.077 1:3 
1000 F28 50.7 57 62.684 75.810 
500 F24 52.8 58.864 64.068 75.896 1:4 
1000 F29 51.3 56.683 61.577 72.668 
500 F25 53.1 58.558 63.274 73.878 
0.65 
1:5 
1000 F30 51 56.365 61.141 71.941 
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EFFECT OF CONCENTRATION OF EMULSIFIER 
 Effect of concentration of emulsifier on the size of 
microspheres were studied and it was found that an optimal 
concentration of emulsifier was required to produce the finest 
stable dispersion. Below this concentration the dispersed 
globules/droplets tend to fuse and produce larger globules because 
of insufficient lowering in interfacial tension, while above the 
optimal concentration no significant decrease in particle size was 
observed, because a high amount of emulsifying agent increases 
the viscosity of the dispersion medium46. In our study it was found 
that there were no much changes as the concentration of emulsifier 
increases. The average mean diameter of the microspheres range 
between 70µm-80µm. The same were given in the following 
Table.No:9 
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Table No 9: Average mean diameter of the microspheres with 
respect to concentration of emulsifier 
Stirring 
speed 
(rpm) 
Drug to 
polyme
r ratio 
Conc. of 
emulsifier 
(%w/v) 
Code 
Length 
no 
(µm) 
Surface 
no 
(µm) 
Volume 
no 
(µm) 
Volume 
Surface 
(µm) 
0.65 F21 45.6 50.646 55.466 66.526 
1.3 F1 49.2 54.415 63.145 85.030 1:1 
1.95 F16 48.3 53.075 57.558 67.692 
0.65 F22 46.5 52.048 57.189 69.045 
1.3 F2 50.4 56.683 62.124 74.622 1:2 
1.95 F17 49.8 55.236 60.012 70.841 
0.65 F23 50.4 56.205 61.345 73.077 
1.3 F3 52.8 57.31 61.32 70.19 1:3 
1.95 F18 52.5 57.784 62.512 73.160 
0.65 F24 52.8 58.864 64.068 75.896 
1.3 F4 53.4 59.47 64.21 74.84 1:4 
1.95 F19 52.5 58.558 63.798 75.728 
0.65 F25 53.1 58.558 63.274 73.878 
1.3 F5 55.5 62.426 68.302 81.764 
500 
1:5 
1.95 F20 55.8 61.555 66.649 78.135 
 
SCANNING ELECTRON MICROSCOPE (SEM) 
 The SEM photographs obtained were given in following 
Figure No: 17-20. The photographs revealed that  the surface 
morphology and size of the microspheres prepared as that the 
formed microspheres were not spherical and discrete. In a study  
by  McGinity47 reported that the polymer precipitation from  the 
organic solvent phase was strongly affected by the rate of diffusion 
of the organic solvent into the aqueous phase. Organic solvents of 
low water solubility resulted in slow polymer precipitation which 
facilitated complete partitioning of the drug into the aqueous 
Chapter 7  Results  & 
Discussion 
 98 
phase, resulting in empty microspheres. On the other hand, highly 
water-miscible solvents did not form droplets but large irregular 
polymer agglomerates upon emulsification due to rapid solvent 
exchange which leads to non uniform and poor encapsulation 
efficiency13. The microspheres prepared were coalesced into a 
continuous mass on drying and lost their properties as individual 
spheres. A similar result has also been reported by Coffin48. The 
microsphere preparation was carried out without secondary 
emulsification step which indicates that this process is essential to 
break the polymer and disperse it into the fine droplets which in 
turn later governed by other factors like concentration of the 
polymer solution, molecular weight of the polymer, homogenization 
speed and emulsifier concentration to obtain the required particle 
size. 
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Fig.No.17:   SEM Photographs of Microspheres  F1 at 500 X 
 
Fig.No.18:   SEM Photographs of Microspheres  F5 at 300 X 
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Fig.No.19:   SEM Photographs of Microspheres  F18 at 1000 X 
 
Fig.No.20:   SEM Photographs of Microspheres  F21 at 2000 X 
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DRUG CONTENT ANALYSIS 
¾ Drug actually loaded 
 The amount of drug Diltiazem hydrochloride loaded to the 
microspheres were analysed at 236.5nm using phosphate buffer 
(pH 7.4) as blank. The results were given in the Table No: 10-12. 
The drug loading with respect to change in the concentration of 
polymer, emulsifier and stirring speed were evaluated. 
 
EFFECT OF CONCENTRATION OF POLYMER 
       The average drug loading efficiency decreases with increasing 
concentration of polymer PCL. The encapsulation efficiency is 
highly influenced by the molecular weight and hydrophilicity of the 
polymers. This might be attributed to higher viscosity of the 
polymeric solution13. In the given Table No:10 it was observed that 
when the polymer concentration was increased 5 times, there is a 
decrease in average drug loading efficiency that is, the drug loading 
efficiency decreased from 61.16% to 37.32% from F1 to F5. Similar 
result was observed in all set of formulations. 
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Table. No. 10 : Average drug loading of microspheres with 
respect to polymer concentration 
Conc of 
emulsifier 
(% w/v) 
Stirring 
speed 
(rpm) 
Drug to 
polymer 
ratio 
code Average drug loading (%w/w) 
1:1 F1 61.16 
1:2 F2 40.8 
1:3 F3 38.6 
1:4 F4 38.46 
 
 
500 
1:5 F5 37.32 
1:1 F6 36.6 
1:2 F7 35.04 
1:3 F8 30.39 
1:4 F9 27.2 
 
 
1000 
1:5 F10 25.03 
1:1 F11 24.13 
1:2 F12 22.29 
1:3 F13 19.5 
1:4 F14 15.99 
1.3 
 
 
1500 
1:5 F15 14.68 
1:1 F16 22.04 
1:2 F17 20.11 
1:3 F18 10.83 
1:4 F19 5.4 
1.95 
 
 
500 
1:5 F20 2.6 
1:1 F21 80 
1:2 F22 72.37 
1:3 F23 64.3 
1:4 F24 54.92 
 
 
500 
1:5 F25 53.4 
1:1 F26 49.46 
1:2 F27 47.8 
1:3 F28 45.37 
1:4 F29 44.15 
0.65 
 
 
1000 
1:5 F30 36.8 
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EFFECT OF STIRRING SPEED 
 The effect of stirring speed on the amount of drug entrapped 
were also studied and found that as the stirring speed increases, 
the average drug loading efficiency decreases. In case of 1:1 drug to 
polymer ratio, it was seen that when the stirring speed was 
increased from 500-1500, the average drug loading efficiency 
decreased from 61.16% to 24.13%. Similar results were seen in all 
set of formulations. This is evident from the following  
Table No: 11 
Table.No.11 : Average drug loading efficiency with respect to 
stirring speed 
Concentration 
of 
emulsifier(%w/v) 
Drug to 
polymer 
ratio 
Stirring 
speed 
(rpm) 
code 
Average 
drug 
loading 
(%w/w) 
500 F1 61.16 
1000 F6 36.6 
 
1:1 
1500 F11 24.13 
500 F2 40.8 
1000 F7 35.04 
 
1:2 
1500 F12 22.29 
500 F3 38.6 
1000 F8 30.39 
 
1:3 
1500 F13 19.5 
500 F4 38.46 
1000 F9 27.2 
 
1:4 
1500 F14 15.99 
500 F5 37.32 
1000 F10 25.03 
 
 
 
 
 
 
 
1:3 
 
1:5 
1500 F15 14.68 
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EFFECT OF CONCENTRATION OF EMULSIFIER 
 The average drug loading efficiency of the microspheres 
decreases with increasing emulsifier concentration. The percent 
encapsulation efficiency of PCL microspheres was found to vary 
within 2.6 to 80%. 
Table.No. 12 : Average drug loading efficiency with respect to 
concentration of emulsifier 
Stirring 
speed 
(rpm) 
Drug to 
polymer 
ratio 
Conc of 
emulsifier 
(%w/v) 
Code 
Average 
drug 
loading 
(%w/w) 
1.3 F1 61.16 
1.95 F16 22.04 1:1 
0.65 F21 80 
1.3 F2 40.8 
1.95 F17 20.11 
 
1:2 
0.65 F22 72.37 
1.3 F3 38.6 
1.95 F18 10.83 1:3 
0.65 F23 64.3 
1.3 F4 38.46 
1.95 F19 5.4 1:4 
0.65 F24 54.92 
1.3 F5 37.32 
500 
1:5 
1.95 F20 2.6 
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  0.65 F25 53.4 
     
  As reported by S.Ravi et al13 the organic solvents acetone 
and ethyl acetate did not encapsulate the drug efficiently and 
produced larger particle size of microspheres compared to 
dichloromethane. The only organic solvent which could 
successfully encapsulate higher amount of drug with smaller size 
of microspheres under selected experimental conditions was 
dichloromethane. This might be due to the optimum solubility of 
dichloromethane in water. These results indicated that 
dichloromethane is a good solvent for the formation of 
microspheres with high entrapment efficiency due to its desirable 
physical properties extremely low solubility in water, ability to 
dissolve large amounts of polymer  and required the lowest heat of 
evaporation 
¾ DRUG RELEASE STUDIES 
 The in-vitro drug release patterns were found by performing 
the experiment as described in the methodology. The results 
obtained were given in Table No: 13-15 and Figure No: 21-26 
Effect of concentration of polymer 
 Effect of concentration of polymer drug release were studied. 
The results indicated that the more sustained effect with increase 
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in the concentration of poly (ε-caprolactone). The in-vitro release 
profiles of microspheres are intended to assist in predicting the 
ultimate behaviour of the given microsphere formulation. The 
release of drug from the microspheres showed a biphasic profile. 
The microspheres showed an initial rapid release of a certain 
amount of drug which was deposited on the surface of the followed 
by a slow and continuous release which corresponds to release of 
drug entrapped in the microspheres. Similar result was observed 
by S.Ravi et al13. In case of F1 to F5 it was observed that the 
percentage of drug release decreased from 53.71 to 32.39%. All set 
of formulations had shown a similar report. 
EFFECT OF STIRRING SPEED 
 Effect of stirring speed on the percentage of drug release was 
studied and it was found that the drug release was high as the 
stirring speed was increased from 500-1500. 
 
 
. 
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Table. No 13: percentage of drug release from microspheres (F1-F30) 
Time Formulati
on code 0 1 2 3 4 5 6 7 8 
F1 0 30.45 32.27 34.04 34.23 40.70 41.08 48.95 53.71 
F2 0 27.42 29.60 31.40 32.29 36.49 41.36 46.10 47.06 
F3 0 23.20 31.18 34.87 35.56 35.93 38.62 39.55 46.11 
F4 0 26.36 28.43 28.56 30.03 33.38 41.29 41.40 45.23 
F5 0 10.75 13.00 14.81 16.25 17.42 24.92 30.78 32.39 
F6 0 36.71 37.01 37.82 38.18 42.94 44.93 47.68 54.03 
F7 0 29.68 33.77 34.50 35.13 39.07 41.99 47.70 53.36 
F8 0 27.25 31.99 33.92 34.49 38.24 44.16 52.01 53.21 
F9 0 24.47 24.88 25.20 27.42 31.88 33.26 35.74 40.72 
F10 0 21.19 21.27 28.79 29.33 29.83 32.64 33.51 34.71 
F11 0 32.08 41.70 42.66 44.94 49.22 51.87 53.49 58.56 
F12 0 29.04 39.67 42.20 44.04 45.72 50.27 52.18 55.51 
F13 0 32.03 34.31 37.40 41.78 44.74 48.94 52.03 53.62 
F14 0 20.16 24.99 25.45 29.02 31.91 34.39 35.14 37.60 
F15 0 6.9 8.4 11.81 18.01 22.30 24.03 22.72 32.96 
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Table. No 13: percentage of drug release from microspheres (F1-F30) continues... 
Time Formula
tion 
code 0 1 2 3 4 5 6 7 8 
F16 0 25.72 30.76 35.93 39.93 41.98 44.43 48.78 52.47 
F17 0 25.18 29.47 34.01 36.76 40.92 45.65 48.44 50.22 
F18 0 23.63 27.83 31.58 34.14 37.21 41.89 45.98 47.99 
F19 0 19.10 22.27 24.86 26.67 27.77 32.39 36.97 40.98 
F20 0 16.38 18 20.38 21.71 23.21 26.54 27.77 29.60 
F21 0 21.27 22.53 23.96 24.51 25.72 39.56 50.41 61.264 
F22 0 22.38 23.68 25.06 29.35 33.30 38.39 50.32 56.74 
F23 0 22.79 26.89 31.32 33.25 36.98 42.49 43.21 48.97 
F24 0 19.36 20.91 22.01 23.48 26.59 30.21 36.61 42.99 
F25 0 18.32 18.82 20.15 22.81 25.30 27.51 30.01 36.97 
F26 0 25.03 28.52 33.68 34.93 39.84 41.76 42.94 46.54 
F27 0 20.11 22.38 24.89 28.79 34.28 36.11 40.80 42.98 
F28 0 22.04 24.60 28.15 31.78 31.96 35.08 38.50 42.02 
F29 0 22.29 25.92 28.37 29.81 33.45 35.33 37.67 38.75 
F30 0 10.83 13.91 14.58 17.97 18.49 19.90 21.95 22.96 
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Table.No. 14: Percentage of drug release from microspheres 
with respect to stirring speed 
Time (hrs) 
 Formulation 
code 
Stirring 
speed 
(rpm) 
0 1 2 3 4 5 6 7 8 
F1 500 0 30.45 32.27 34.04 34.23 40.70 41.08 48.95 53.71 
F6 1000 0 36.71 37.01 37.82 38.18 42.94 44.93 47.68 54.03 
F11 1500 0 32.08 41.70 42.66 44.94 49.22 51.87 53.49 58.56 
F2 500 0 27.42 29.60 31.40 32.29 36.49 41.36 46.10 47.06 
F7 1000 0 29.68 33.77 34.50 35.13 39.07 41.99 47.70 53.36 
F12 1500 0 29.04 39.67 42.20 44.04 45.72 50.27 52.18 55.51 
F3 500 0 23.20 31.18 34.87 35.56 35.93 38.62 39.55 46.11 
F8 1000 0 27.25 31.99 33.92 34.49 38.24 44.16 52.01 53.21 
F13 1500 0 32.03 34.31 37.40 41.78 44.74 48.94 52.03 53.62 
F4 500 0 26.36 28.43 28.56 30.03 33.38 41.29 41.40 45.23 
F9 1000 0 24.47 24.88 25.20 27.42 31.88 33.26 35.74 40.72 
F14 1500 0 20.16 24.99 25.45 29.02 31.91 34.39 35.14 37.60 
F5 500 0 10.75 13.00 14.81 16.25 17.42 24.92 30.78 32.39 
F10 1000 0 21.19 21.27 28.79 29.33 29.83 32.64 33.51 34.71 
F15 1500 0 6.9 8.4 11.81 18.01 22.30 24.03 22.72 32.96 
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EFFECT OF CONCENTRATION OF EMULSIFIER 
 Formulation with low concentration of emulsifying agent also 
showed a fast release may be due to porous structure. It is 
confirmed from the given Table No:15 that as the concentration of 
emulsifier increased from 0.65% to 1.95%, the release of drug from 
the prepared microspheres decreased from 61.26% to 52.47%. 
 In the present study, dissolution studies had been conducted 
for a period of 8 hours. During the first hour one-third of the 
release has taken place. A total of 50% release only had been 
observed during the eight hour dissolution study. Further studies 
could have been done by extending the time upto 16 hours for 
knowing the complete release pattern. 
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Table. No 15: percentage of drug release from microspheres with respect to concentration of 
emulsifier 
Time (hrs) Concentration 
of emulsifier 
(% w/v) 
Formulation 
code 
0 1 2 3 4 5 6 7 8 
0.65 F21 0 21.27 22.53 23.96 24.51 25.72 39.56 50.41 61.264 
1.3 F1 0 30.45 32.27 34.04 34.23 40.70 41.08 48.95 53.71 
1.95 F16 0 25.72 30.76 35.93 39.93 41.98 44.43 48.78 52.47 
0.65 F22 0 22.38 23.68 25.06 29.35 33.30 38.39 50.32 56.74 
1.3 F2 0 27.42 29.60 31.40 32.29 36.49 41.36 46.10 47.06 
1.95 F17 0 25.18 29.47 34.01 36.76 40.92 45.65 48.44 50.22 
0.65 F23 0 22.79 26.89 31.32 33.25 36.98 42.49 43.21 48.97 
1.3 F3 0 23.20 31.18 34.87 35.56 35.93 38.62 39.55 46.11 
1.95 F18 0 23.63 27.83 31.58 34.14 37.21 41.89 45.98 47.99 
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Table. No 15: percentage of drug release from microspheres  with respect to concentration of 
emulsifier continues.. 
Time (hrs) Concentration 
of emulsifier 
(% w/v) 
Formulation 
code 
0 1 2 3 4 5 6 7 8 
0.65 F24 0 19.36 20.91 22.01 23.48 26.59 30.21 36.61 42.99 
1.3 F4 0 26.36 28.43 28.56 30.03 33.38 41.29 41.40 45.23 
1.95 F19 0 19.10 22.27 24.86 26.67 27.77 32.39 36.97 40.98 
0.65 F25 0 18.32 18.82 20.15 22.81 25.30 27.51 30.01 36.97 
1.3 F5 0 10.75 13.00 14.81 16.25 17.42 24.92 30.78 32.39 
1.95 F20 0 16.38 18 20.38 21.71 23.21 26.54 27.77 29.60 
 
Chapter    Results 
 113 
 
Fig.No. 21 : Drug Release of Prepared microspheres  
( F1-F5) 
 
 
 
 
 
Fig.No. 22  : Drug Release of Prepared microspheres  
( F6-F10) 
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Fig.No. 23 : Drug Release of Prepared microspheres  
( F11-F15) 
 
Fig.No.24 : Drug Release of Prepared microspheres  
( F16-F20) 
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Fig.No. 25 : Drug Release of Prepared microspheres  
( F21-F25) 
 
 
Fig.No. 26 : Drug Release of Prepared microspheres  
( F26-F30) 
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KINETICS OF DRUG RELEASE 
In-vitro data obtained for Poly (ε-caprolactone) microspheres 
containing Diltiazem hydrochloride were used to determine the 
dissolution kinetics. The drug release data of Diltiazem 
hydrochloride were fitted to models representing Zero order 
(cumulative amount of drug released vs time), First order (log 
cumulative percentage of drug remaining vs time), Higuchi’s 
(cumulative percentage of drug released vs square root of time), 
and Korsmeyer’s equation (log cumulative percentage of drug 
released vs log time) kinetics to know the release mechanisms. The 
data were processed for regression analysis using MS-EXCEL 
statistical functions. These data indicated that the drug release 
followed the diffusion controlled model as described by Higuchi’s 
square root of time equation.  
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Table  16:   Drug release kinetics for poly (ε-caprolactone) 
microspheres 
Formulation 
Zero 
Order 
R2 
First 
Order 
R2 
Higuchi's Plot 
R2 
Korsmeyer's 
Plot 
R2 
F1 0.778 0.852 0.918 0.444 
F2 0.784 0.856 0.933 0.451 
F3 0.721 0.788 0.920 0.457 
F4 0.774 0.839 0.919 0.449 
F5 0.934 0.935 0.907 0.636 
F6 0.65 0.741 0.849 0.394 
F7 0.762 0.840 0.916 0.439 
F8 0.826 0.892 0.945 0.472 
F9 0.754 0.813 0.910 0.441 
F10 0.713 0.765 0.918 0.457 
F11 0.727 0.834 0.927 0.439 
F12 0.734 0.832 0.934 0.452 
F13 0.763 0.860 0.941 0.444 
F14 0.778 0.837 0.954 0.477 
F15 0.953 0.947 0.953 0.772 
F16 0.82 0.900 0.974 0.485 
F17 O.836 0.910 0.978 0.491 
F18 0.844 0.911 0.976 0.494 
F19 0.856 0.905 0.974 0.506 
F20 0.794 0.837 0.954 0.487 
F21 0.868 0.835 0.813 0.548 
F22 0.910 0.909 0.908 0.541 
F23 0.855 0.917 0.978 0.503 
F24 0.866 0.890 0.919 0.513 
F25 0.836 0.871 0.934 0.494 
F26 0.783 0.857 0.958 0.470 
F27 0.885 0.933 0.980 0.524 
F28 0.803 0.865 0.958 0.477 
F29 0.755 0.819 0.943 0.460 
F30 0.835 0.865 0.978 0.550 
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SUMMARY 
 The current study “Formulation and evaluation of 
Diltiazem hydrochloride microspheres for Oral Controlled 
Release Drug Delivery using Poly (ε-caprolactone)” was 
formulated and evaluated. The results obtained from the above 
study can be summarized  as follows. 
 Literatures pertaining to microspheres, poly (ε-caprolactone) 
and drug Diltiazem hydrochloride were surveyed thoroughly 
and documented. 
 Standard graph was prepared by using UV 
spectrophotometer with phosphate buffer pH 7.4 as solvent. 
 Microspheres containing the drug and varying concentration 
of polymer, stirring speed and emulsifier was prepared by 
solvent evaporation technique. 
 The prepared microspheres were evaluated. 
COMPATIBILITY STUDIES 
IR spectral analysis 
  The IR spectrums revealed that there were no interaction 
between the drug and polymer. 
 
 
PHYSICAL CHARACTERISATION 
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Particle size and size distribution analysis 
9 The particle size distribution of each formulation was very 
 well within the narrow size range. 
9 Increases in concentration of poly (ε-caprolactone) the 
 average mean diameter of the microspheres were increased. 
9 When the stirring speed was increased there was a decrease 
 in average mean diameter of the particles. 
9 An optimal concentration of emulsifier is required to produce 
 the desired particle size. 
Scanning electron microscope 
9 The formed microspheres were not spherical and discrete. 
 The microspheres prepared were coalesced into a continuous 
 mass on drying and lost their properties as individual 
 spheres. 
DRUG CONTENT ANALYSIS 
9 Increasing the concentration of poly (ε-caprolactone) resulted 
 in decrease in drug loading efficiency. 
9 Increase in concentration of emulsifier, decrease in drug 
 loading efficiency. 
9 As the stirring speed increases, drug loading efficiency 
 decreases. 
IN-VITRO DRUG RELEASE STUDIES 
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9 The in-vitro drug release studies revealed that 30-40% of 
drug were released in 1st hour and latter it was sustained. 
The release of drug from the microspheres had shown a 
biphasic profile.  
9 The microspheres showed an initial rapid release of a certain 
amount of drug which was deposited on the surface of the 
followed by a slow and continuous release which corresponds 
to release of drug entrapped in the microspheres. 
9 Increase in concentration of poly (ε-caprolactone), the drug 
release rate becomes more sustained. 
9 Drug release was high as the stirring speed was increased 
 from 500-1500. 
KINETICS OF DRUG RELEASE 
9 The results indicated that the drug release from formulation 
followed the diffusion controlled model as described by 
Higuchi’s square root of time equation. 
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CONCLUSION 
 The work entitled “Formulation and Evaluation of 
Diltiazem hydrochloride Microspheres for Oral Controlled 
Release Drug Delivery using Poly (ε-caprolactone)” was 
formulated and evaluated. The study can be concluded that from 
the investigations a proper selection of formulation parameters are 
important to achieve the desired particle size, drug loading 
efficiency and to sustain the release of drug from PCL 
microspheres. It was observed that particle size increased as the 
polymer concentration increased. A secondary emulsification 
process is required where the particle size can be further reduced 
which was not carried in our present work. Increase in stirring 
speed also decreases the particle size. In case of drug loading 
efficiency, when the concentration of polymer and emulsifier was 
increased, the drug loading efficiency decreased. Increase in 
stirring speed also caused a decrease in drug loading efficiency. 
The release of drug from the microspheres was sustained when the 
concentration of polymer is increased. When the stirring speed was 
increased from 500-1500 rpm, the drug release was high. The in-
vitro release profiles of drug from all formulations could be best 
expressed by Higuchi’s equation. 
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